ArticleAdvanced healthcare materials2025
Multiscale Profiling of Nanoscale Metal-Organic Framework Biocompatibility and Immune Interactions.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Reprogramming the oxidative microenvironment: Antioxidant nanoplatforms for central nervous system repair.Materials today. Bio · 2026Review
- Selective heavy-metal sequestration and rare-earth element recovery using metal-organic frameworks.Nature protocols · 2026Review
- Metal-Organic Frameworks in Food Biotechnology: Opportunities, Challenges, and Future Perspectives for Probiotic Delivery, Precision Fermentation, and Circular Food Systems.Nanomaterials (Basel, Switzerland) · 2026Review
- DNA-mimic for Specific Surface Functionalization of Zr-MOFs for Bacterial Targeting.Angewandte Chemie (International ed. in English) · 2026Article
- From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics.International journal of molecular sciences · 2026Review
- Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Combining Fluorescence and Magnetic Resonance Imaging in Drug Discovery-A Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Biotic Transformation of Abiotically Stable Nanoscale UiO-66 Metal-Organic Framework byACS nano · 2025Article
- Multiscale Profiling of Nanoscale Metal-Organic Framework Biocompatibility and Immune Interactions.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The clinical translation of metal-organic frameworks (MOFs) - a promising class of porous materials for nanomedicine - is hindered by a poor understanding of their complex interactions with the immune system and in vivo immunotoxicity. To address this gap, a hierarchical "Safety-by-Design" pipeline is established and validated, integrating machine learning (ML) with ex vivo human blood studies and targeted in vivo models. This multi-stage workflow enables the systematic profiling of MOF immunotoxicity, de-risking their development. The power of this approach is demonstrated using four clinically relevant MOFs - NU-901, PCN-222, UiO-66, and ZIF-8 - revealing distinct, framework-dependent immune fingerprints. The initial in silico screening correctly flagged NU-901 and ZIF-8 as potential hazards to human health. These predictions are subsequently validated ex vivo, where NU-901 is confirmed to be selectively cytotoxic to CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.